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Introduction
Patients with ischemic limb and cardiac disease suffer from vascular insufficiencies. There is, therefore, a need to increase blood flow and promote functional collateral circulation in these patients. The discovery of vascular endothelial growth factor (VEGF) as a stimulator of blood vessel formation provided a new avenue for the treatment of vascular insufficiencies. The VEGF signaling pathway promotes angiogenesis [1] . The major ligand VEGF-A binds to and activates VEGFR-1, VEGFR-2 and VEGFR 1-2 receptors. Unlike VEGF-A, placental growth factor (PlGF-1) specifically activates VEGFR-1, but not neuropilin or VEGFR-2, thus serves a unique tool for studying VEGFR-1 signaling (Fig. 1A) [2, 3] . Although PlGF-1 was demonstrated to regulate interand intramolecular cross talk between the VEGFR-1 and VEGFR-2, this regulation is mediated through an indirect pathway rather than direct binding to VEGFR-2 [4] . Similarly, VEGF-E, a virus-origin VEGF homologue, exclusively binds to and activates VEGFR-2, and not VEGFR-1 or VEGFR-3 ( Fig. 1A) [5, 6, 7] . However, no natural ligands are identified that activate VEGFR 1-2 without activating VEGFR-1 homodimers.
The VEGF signaling pathway is tightly regulated as the process of angiogenesis regulates blood vessel formation and wound healing, and dysregulation leads to tumor growth and ischemic disease [8, 9, 10, 11] .
VEGF-A levels are maintained within a narrow concentration range to ensure successful function [11, 12] . A soluble form of VEGFR-1 (sFlt-1) acts as a natural antagonist to VEGF-A and PlGF-1 to suppress VEGF signaling [13, A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT 4 14]. Prior to the development of tools to study VEGFR 1-2 heterodimer function, it was reported that VEGFR-1 receptor acts as a negative regulator of VEGF signaling pathway. The activation of VEGFR-1 receptor limited trophoblast cell DNA synthesis [15] , inhibited VEGFR-2 mitogenic activity [16] , downregulated endothelial cell proliferation [17] and angiogenesis [18] . However, it is not clear whether VEGFR-1 homomeric or VEGFR 1-2 heteromeric receptor mediates the inhibition of VEGFR-2 activity. To dissect the function of VEGFR 1-2 in endothelial cells, we have generated a unique VEGFR 1-2 -specific ligand VEGF-E:PlGF-1 (VE:Pl) that comprises of one monomer of VEGFR-2-specific ligand (VEGF-E) and one monomer of VEGFR-1-specific ligand (PlGF-1) [19] . A recent study revealed that the VEGF-E:PlGF-1 ligand specifically activates heterodimeric VEGFR 1-2 to inhibit VEGF-A-induced prostacyclin release, phosphorylation of ERK1/2 MAP kinase and mobilization of intracellular calcium in endothelial cells [19] . This inhibition is exclusively conducted through the VEGFR 1-2 heterodimer as VEGF-E:PlGF-1 does not activate VEGFR-1 or VEGFR-2 homodimers. We know this to be the case because we engineered porcine aortic endothelial (PAE) cells, which do not express VEGF receptors, to express either VEGFR-1 or VEGFR-2 [19] . In these cells, VEGF-E:PlGF-1 had no effect on VEGF receptor phosphorylation [19] . However, both the mechanism of how VEGFR 1-2 modulates VEGF signaling and the relationship with VEGFR-1 homodimers remain unknown.
Our novel VEGF-E:PlGF-1 ligand which binds only to the VEGFR [1] [2] heterodimer receptor (Fig. 1A) provides the unique opportunity to address the role of VEGFR 1-2 .
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Although VEGFR-1 signaling activates many pathways including phosphatidylinositol-3 kinase (PI3K), Akt, p38, and ERK1/2, PI3K appears to be a central regulator in specific cells [20] . Stimulation of VEGF in the cells exclusively expressing VEGFR-1 resulted in a strong increase of PI3K/Akt phosphorylation [21] and inhibition of VEGFR-1 activity suppressed PI3K-Akt signaling in mice [22] . Our previous study showed that VEGFR-1 activates the PI3K/Akt pathway to regulate nitric oxide release in endothelial cells [23] .
Moreover, VEGFR-2 preferentially utilizes the PLCγ-PKC-MAPK pathway, but not PI3K/Akt, for signaling, further confirming the preference of PI3K in the VEGFR-1 mediated signaling pathway [24] . Therefore, we tested the possibility that VEGFR 1-2 heterodimer activates PI3K to modulate VEGFR-2 activity to negatively regulate VEGF signaling in endothelial cells.
In the present study, we demonstrated that the activation of VEGFR [1] [2] inhibited, while inhibition of PI3K, promoted VEGFR-2 phosphorylation.
Furthermore, inhibition of PI3K abrogated the VEGFR 1-2 mediated inhibition of VEGFR-2 phosphorylation. Finally, we confirmed functionally that the activation of VEGFR 1-2 significantly suppressed VEGFR-2 induced in vitro angiogenesis and this suppression could be abolished by inhibition of PI3K pathway.
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Methods and Materials
Reagents and antibodies
Recombinant growth factors, VEGF-A, VEGF-E and PlGF-1, were purchased from RELIATech (Brauschweig, Germany). VEGF-E:PlGF-1 was generated inhouse as described previously [19] . LY294002 was purchased from SigmaAldrich (USA).
Rabbit antibodies against phosphorylated VEGF receptor-2 at tyrosine Y951 
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Cell culture
Human umbilical vein endothelial cells (HUVECs) were purchased from Cellworks (Buckingham, UK) and cultured in M199 medium as described previously [18] . Experiments were performed on third or fourth passage
HUVECs. The engineered stable porcine aortic endothelial cells (PAECs)
containing human VEGF receptor 2 (PAER-2) or both VEGF receptor 1 and 2
(PAER-1:R-2) were maintained in Ham F-12 supplemented with 10 % FCS with the addition of G418 [25] .
siRNA against VEGFR-1
The small interfering RNA (siRNA) against human VEGFR-1 and a mismatch universal control siRNA were described previously [19] . The sequences of siRNA duplex to VEGFR-1 are sense, 5′-UGAUGGCCUUACACUGAAAtt-3′; antisense, 5′-UUUCAGUGUAAGGCCAUCAtt-3′. The non-targeting control siRNA (D-001206-13) was purchased from Dharmacon.
In vitro cell transfection
The siRNA was transfected into HUVECs using an AMAXA nucleofector 
Western Blotting
The procedure for western blot was described previously [26] . Briefly, total protein from PAE cells or HUVECs was lysed in RIPA buffer. Protein concentration was analyzed using Bradford assay. 30 µg RIPA lysate was separated on 8-12 % SDS-PAGE and transferred into Hybond N+ membrane.
Primary antibody diluted 1:1000 was used to incubate with the membrane for 4-6 h and then washed with TBS-T buffer three times of 15 mins. Secondary antibody diluted 1: 5000-10,000 was used to incubate with the membrane at room temperature for 1 h and then followed by three 20 mins washes. Finally, the membrane was exposed in a dark room for 1-5 mins using EZ-ECL kit.
Densitometric analysis was performed across three independent experiments using ImageJ software. Protein densitometric levels were normalized to respective loading controls.
Cell proliferation assay
Cell proliferation assay was carried out using CyQUANT® NF Cell 
In vitro tube formation assay
Formation of capillary-like structures on growth factor reduced Matrigel was determined as previously described [18] . Briefly, cells ( 
Statistical analysis
All data were collected from at least three independent experiments and expressed as a mean ± S.E.M. Statistical comparisons were performed using Student's t-test or one-way ANOVA. Statistical significance was set at a value of p<0.05.
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Results
Activation of VEGFR 1-2 heterodimeric and not VEGFR-
homomeric receptor inhibits VEGFR-2 receptor phosphorylation
The VEGFR-2 phosphorylation upon VEGF-A stimulation was measured at different time points. The phosphorylation of VEGFR-2 was detected 5 minutes after stimulation and remained for least 15 minutes without a significant decrease (Fig. S1 ). Thus, the following experiments, if not stated differently, were performed within a 5 to 10 minute range after growth factor stimulation.
To investigate whether deletion of VEGFR-1 affects VEGFR-2 activation, the phosphorylation of VEGFR-2 was measured in HUVECs with transfection of siVEGFR-1 under the stimulation of VEGF-A. HUVECs transfected with siVEGFR-1 showed an increase in phosphorylation at the two major tyrosine phosphorylation sites (Y951 and Y1175) in VEGFR-2 compared to the control siRNA transfected cells (Fig. 1B ). This data implies that the presence of VEGFR-1 inhibits VEGFR-2 phosphorylation under VEGF stimulation.
As knock-down of VEGFR-1 affects both the VEGFR-1 homodimer and VEGFR 1-2 heterodimer, we further investigated whether the homodimer or heterodimer of VEGFR-1 negatively regulates VEGFR-2 phosphorylation.
HUVECs were pre-treated with PlGF-1 (which only stimulates VEGFR-1 homodimer, Fig 1A) and subsequently stimulated with a vehicle or VEGF-E.
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The phosphorylation levels of VEGFR-2 at tyrosine Y951 and Y1175 were measured by Western blot. As expected, PlGF-1 treatment did not cause phosphorylation of VEGFR-2 ( Fig. 1C) . Interestingly, cells pre-treated with
PlGF-1 did not show any difference in VEGFR-2 phosphorylation at both tyrosine sites under VEGF-E stimulation compared to VEGF-E only treated cells (Fig. 1C) . Therefore it demonstrated that activation of the VEGFR-1 homodimer does not affect VEGFR-2 phosphorylation. We went on to test whether activation of VEGFR 1-2 heterodimer negatively regulates VEGFR-2 phosphorylation using VEGF-E:PlGF-1 ligand (which only activates VEGFR [1] [2] heterodimer, Fig 1A) . HUVECs were either (i) pre-treated with VEGF-E:PlGF-1 ligand and then stimulated with VEGF-E; or (ii) simultaneously treated with VEGF-E:PlGF-1 and VEGF-E. These conditions were compared to VEGF-E only treated cells (Fig. 1D ). VEGF-E:PlGF-1 pre-treatment significantly reduced VEGFR-2 phosphorylation at both Y951 and Y1175 sites compared to cells treated with VEGF-E alone. Interestingly, simultaneous treatment of VEGFE and VEGF-E:PlGF-1 had no inhibitory effect on VEGFR-2 phosphorylation (Fig. 1D ). Notably, the phosphorylation level of VEGFR-2 was higher in the VEGF-E:PlGF-1 and VEGF-E co-treated cells compared to VEGF-E only treated cells, probably due to the additive effect caused by VEGF-E:PlGF-1 (Fig. 1D) . Taken together, the data suggest that VEGFR [1] [2] rather than VEGFR-1 homomeric receptor negatively regulates VEGFR-2 phosphorylation (Fig. 1E) .
Inhibition of PI3K pathway increases VEGFR-2 phosphorylation
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Evidence from earlier studies suggest that the PI3K signaling pathway is involved in the downstream signaling of VEGFR-1 to regulate VEGFR-2 activity [22, 23] . Thus we tested whether inhibition of PI3K could alter the phosphorylation level of VEGFR-2 under stimulation of VEGF-A, VEGF-E and VEGF-E:PlGF-1 separately or in combination. HUVECs were pre-treated with the PI3K inhibitor LY294002 and subsequently treated with VEGF-A. VEGFR-2 phosphorylation levels at both Y951 and Y1175 sites were significantly increased in the cells pre-treated with LY294002 ( Fig. 2A) .
Since VEGF-A can activate both VEGFR-1 homodimeric and VEGFR [1] [2] heterodimeric receptors, we further investigated which receptor was signaling through PI3K to prevent VEGFR-2 phosphorylation. As before, HUVECs were pre-treated with LY294002 and PlGF-1 separately or in combination. The pretreated cells were subsequently stimulated with VEGF-E. Not surprisingly, the phosphorylation level of VEGFR-2 in the cells pre-treated with LY294002 and PlGF-1 did not show a significant difference compared to cells pre-treated with PlGF-1 alone (Fig. 2B ). However, VEGF-E stimulation induced a dramatic increase in phosphorylation of VEGFR-2 at both Y951 and Y1175 sites in HUVECs co-pre-treated with LY294002 and VEGF-E:PlGF-1 compared to those only pre-treated with VEGF-E:PlGF-1 (Fig. 2C ). This data suggests that VEGFR 1-2 heterodimeric and not VEGFR-1 homodimer receptor regulate VEGFR-2 phosphorylation via PI3K (Fig. 2D) .
Inhibition of PI3K abrogates the VEGF-E:PlGF-1
A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT
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Since our data suggest that VEGFR 1-2 heterodimeric receptor regulates VEGFR-2 phosphorylation via PI3K, we tested whether inhibition of PI3K could abrogate the VEGF-E:PlGF-1 mediated inhibition of VEGFR-2 signaling.
Firstly, we confirmed that pre-treatment of VEGF-E:PlGF-1 is capable of activating PI3K/Akt signaling pathway as measured by Akt (Ser473) phosphorylation in endothelial cells (Fig. 3A, 1 Fig. 3E ).
Furthermore, we tested our concept in the PAE cells which were engineered to only express VEGFR-2 receptors [19] . PAE-R2 cells co-pre-treated with VEGF-E:PlGF-1 and LY294002 did not show a significant difference in the
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15 phosphorylation of VEGFR-2 under VEGF-E stimulation compared to VEGF-E:PlGF-1 pre-treated cells (Fig. 3G) . The densitometric analysis also showed no significant difference between cells pre-treated with VEGF-E:PlGF-1 and LY294002 and those pre-treated with VEGF-E:PlGF-1 only (Fig. 3H) . Notably, a VEGF-E:PlGF-1 stimulation did not change the phosphorylation level of VEGFR-2 compared to vehicle control (Fig. 3G, 1 st and 3 rd lanes). This data confirm that VEGF-E:PlGF-1 does not activate VEGFR-2 homodimers as reported earlier [19] .
Inhibition of PI3K enhances growth factor-mediated angiogenesis
Previous data demonstrated that PI3K regulates VEGFR-2 and ERK phosphorylation [28, 29] . We therefore tested whether inhibition of PI3K could enhance endothelial cell biological function. As a main feature of endothelial cells, the in vitro angiogenic ability was investigated in the cells with inhibited
PI3K. PAER-1:R-2 cells were pre-treated with LY294002 and plated on
Matrigel under stimulation of VEGF-A (Fig. S2A) . The total tube length of cells pre-treated with LY294002 was significantly increased compared to non-pretreated cells (Fig. S2B) , further confirming that inhibition of PI3K could enhance endothelial cell biological function.
Inhibition of PI3K partially abrogates VEGF-E:PlGF-1
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To prove VEGF-E:PlGF-1 acts through PI3K to inhibit VEGFR-2 activity, we investigated whether inhibition of PI3K could abrogate the VEGF-E:PlGF-1 mediated inhibition of VEGFR-2 biological activity in endothelial cells.
HUVECs were seeded with a density of 2000 cells/well in a 96-well plate and pre-treated with LY294002 and VEGF-E:PlGF-1, alone or in combination. To further test our theory in angiogenesis, HUVECs were pre-treated with VEGF-E:PlGF-1 alone or with LY294002 and subsequently plated on Matrigel under stimulation of VEGF-E (Fig. 4B) . The total tube length formed in the cells pre-treated with VEGF-E:PlGF-1 was decreased under VEGF-E stimulation compared to non-pre-treated or VEGF-E:PlGF-1 and VEGF-E simultaneously treated cells (Fig. 4C ). In line with our hypothesis, HUVECs VEGF-E did not show an inhibitory effect on VEGFR-2 phosphorylation (Fig.   1D ). The inhibition of tube formation in simultaneously treated cells was probably due to the prolonged incubation with VEGF-E:PlGF-1 (6-8 hours to
5-10 minutes).
A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT
18
Discussion
VEGF-A has a lower affinity for VEGFR-2 but this receptor is responsible for endothelial cell proliferation and migration [30] , whereas VEGFR-1 homomeric receptor is reported to negatively regulate VEGF signaling [15, 16, 17, 18] .
The density of VEGFR-1 on the cell surface is less than tenfold compares to those of VEGFR-2 [31] and therefore the majority of VEGFR-1 subunits form VEGFR 1-2 heteromeric receptors [32] . The role of VEGF signaling via the VEGFR 1-2 has eluded us due to the lack of a ligand that specifically binds to In this study, we identified that VEGFR 1-2 receptor and not VEGFR-1 homomeric receptor activates PI3K to suppress VEGFR-2 receptor activity and the inhibition of PI3K could restore the VEGFR 1-2 receptor mediated inhibition of VEGFR-2 activity.
The mechanism by which VEGFR 1-2 inhibits VEGFR-2 activity is still not clear.
Our study confirms the ability of VEGFR 1-2 itself to induce biological signaling
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ACCEPTED MANUSCRIPT 19 and activities (Fig. 4A ) [19] . However, it is not clear whether VEGFR 1-2 inhibits VEGFR-2 signaling through its downstream effector or direct interaction. Our present study implies that VEGFR 1-2 regulates VEGFR-2 signaling through an indirect rather than direct interaction since only pretreatment of VEGF-E:PlGF-1 is able to inhibit VEGFR-2 phosphorylation (Fig. 1D) . Notably, the simultaneous stimulation of VEGF-E:PlGF-1 and VEGF-E leads to higher VEGFR-2 phosphorylation compared to VEGF-E only treatment (Fig. 1D) . The loss of inhibition on VEGFR-2 phosphorylation by VEGF-E:PlGF-1 is probably due to the short duration (5-10 minutes) stimulation which is not enough to trigger the downstream effectors. Indeed, the simultaneously addition of VEGF-E:PlGF-1 and VEGF-E in a relative long experiment setting, such as tube formation and cell proliferation (6-8 and 48-72 hours), did inhibit VEGF-E mediated biological activity ( Fig. 4A and B) . Moreover, our data highlights the possibility of PI3K in the inhibition of VEGFR-2 signaling. However, PI3K is also demonstrated to play an important role in regulating endothelial proliferation, migration and survival through VEGFR-2 signaling [36, 37]. Thus, the PI3K pathway may play a complex role in the regulation of VEGF signaling.
As mentioned earlier, only cells that received a pre-treatment of VEGF-E:PlGF-1 exhibited an inhibitory effect and not in the cells simultaneously treated with VEGF and VEGF-E:PlGF-1. This observation further implies that temporal activation of PI3K may affect its subsequent biological activity. In line with this, the spatial and temporal regulation of PI3K is demonstrated to be required for proper chemotaxis and hematopoietic stem cell maintenance [38, 39] . In addtion, the pretreatment of VEGF-E:PlGF-1 may also lead to the rapid internalization and endocytosis of cell surface VEGFR-2 receptor thus
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inhibiting VEGF mediated biological activity. Our previous study demonstrated the rapid internalization and trafficking of VEGFR-2 receptor upon VEGF-E:PlGF-1 stimulation [19] . Other studies also confirmed that VEGF receptor internalization and endocytosis is required for endothelial cell biological functions, such as ERK1/2 activation [40] , angiogenesis [41] and cell recovery after wounding [42] . To gain a better understanding of VEGFR 1-2 biological function, further investigation is warranted.
Anti-VEGF therapies via neutralizing VEGF ligand or VEGFR-2 inhibition are in use but effectiveness in cancer treatment is limited [43, 44] . Likewise, therapeutic angiogenesis used to treat limb ischemia [45] , peripheral artery [46] and coronary artery disease [47] by promoting VEGF signaling have not been a great success and clinical trials are inconclusive [48, 49] . This is thought to be due to possible "off-target" effects of the currently available VEGF pathway activators and inhibitors [50] . Our study highlights that the role of VEGFR 1-2 in the regulation of VEGF signaling should be considered when designing agents which regulate VEGF receptor activity. The agents that regulate VEGFR-2 receptor might also target VEGFR 1-2 heterodimeric receptor and subsequently disrupt the natural inhibitory mechanisms designed to regulate VEGFR-2 activity.
In conclusion, our data demonstrates that VEGFR 1-2 heteromeric receptor and not VEGFR-1 homomeric receptor is responsible for limiting VEGF signaling through downregulation of VEGFR-2 phosphorylation and thus attenuates VEGFR-2 activity. Furthermore, we confirmed that PI3K pathway acts 
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